

Comparative study of the efficacy and safety of intranasal ketamine and midazolam for the acute treatment of migraine with prolonged aura

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 06/12/2013	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr PJ Goadsby

Contact details

Headache and Migraine Group
Institute of Neurology
Queen Square
London
United Kingdom
WC1N 3BG
+44 020 7829 8749
peterg@ion.ucl.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0263104924

Study information

Scientific Title

Study objectives

A comparative study of the efficacy and safety of intranasal ketamine and midazolam for the acute treatment of migraine with prolonged aura and familial hemiplegic migraine.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Migraine

Interventions

Clinical trial:

1. Intranasal ketamine
2. Midazolam

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Patient diary-based observations of progression of aura

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/09/2001

Completion date

01/12/2005

Eligibility

Key inclusion criteria

30 Patients from Neurology.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

30

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/09/2001

Date of final enrolment

01/12/2005

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Headache and Migraine Group

London
United Kingdom
WC1N 3BG

Sponsor information

Organisation

Department of Health (UK)

Sponsor details

Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type

Government

Website

<http://www.doh.gov.uk>

Funder(s)

Funder type

Government

Funder Name

University College London Hospitals NHS Trust (NHS R&D Support Funding)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	12/02/2013		Yes	No